Navigation Links
FDA approves MyocondaR IND for MAP in Crohn's Disease

SYDNEY, Australia 24 April 2007. Giaconda Ltd (ASX: GIA) today announced that the US Food and Drug Administration (FDA) has approved the Company's Investigational New Drug application (IND) for the clinical development of MyocondaR to treat patients with Crohn's Disease infected with Mycobacterium avium spp paratuberculosis (MAP).

The Company understands that its lead product, MyocondaR, is the first therapy to be submitted to the FDA for this indication. There are no anti-MAP therapies approved for use in Crohn's Disease.

MAP is considered as the most likely infectious cause of Crohn's Disease. Current treatments on the market are indicated for symptomatic treatment of the disease. On the basis of clinical experience, Giaconda believes that by treating and controlling the underlying MAP infection, MyocondaR will offer a valuable therapy to patients who do not respond to currently available therapies. Current research indicates that between 40 - 50% of Crohn's patients are MAP positive.

Patients can be diagnosed with MAP infection using a blood test. The IND approval allows the Company to commence the next clinical trial of MyocondaR in the USA. The Company is continuing preparations for the multi-centre, double blind, placebo controlled, Phase II/III trial. Before the trial commences the Company will conduct pharmacokinetics investigations, test the drug manufacturing for the trial and make ethics submissions to the various clinical trial centres. It is anticipated that the trial will commence by the end of 2007.

Since the previous Phase III trial, which was undertaken prior to Giaconda acquiring MyocondaR, an alternative development program, substantially different from its predecessor, has been undertaken based on further understanding of the mechanism of action of MyocondaR. This has resulted in a new product based on the original research. The Phase II/III trial is necessary due to the changes in the drug form at which will now be an all-in-one oral capsule, the increased dosages and the new indication being sought.

"We are very pleased to have reached this key milestone in the development of MyocondaR. There is clearly a need for this type of therapy for the substantial subset of Crohn's Disease patients infected with MAP who are not well served by current therapies," said Patrick McLean, CEO of Giaconda "Giaconda is now another step closer to achieving its aim of bringing this product to market as soon as possible for the benefit of patients who are infected with MAP.

The development of MyocondaR is supported by a significant number of opinion leaders in the field". About Giaconda Limited Giaconda Limited is a biotechnology company involved in developing and licensing innovative and cost effective medical therapies in the field of gastroenterology. Giaconda's products are targeted towards the treatment of serious conditions that are not adequately addressed by any existing therapy. In this way, Giaconda's products are intended to satisfy these significant unmet medical needs of the gastrointestinal market. The Giaconda portfolio consists of five products, all of which are novel combinations of known compounds. Giaconda has two lead products, MyocondaR for the treatment of Crohn's Disease and HelicondaR for the treatment of resistant Helicobacter pylori infection. For more information please visit www.giacondalimited.com

About MyocondaR -
A Combination Antibiotic Therapy for the Treatment of Crohn's Disease MyocondaR, the Company's Anti-MAP therapy for the treatment of Crohn's Disease is a combination of three registered anti-mycobacterial drugs - rifabutin, clarithromycin and clofazimine. These three drugs are widely marketed world-wide for the treatment of mycobacterial and other infections. MyocondaR presents these three compounds in a specific patented combin ation. MyocondaR is based on the proposition that MAP infection is a significant factor in Crohn's Disease. Prof. Borody has long been at the forefront of this approach, which is gaining increasing acceptance among gastrointestinal specialists worldwide. Prof. Borody has published significant data demonstrating that patients treated with anti-MAP combination therapy such as that found in MyocondaR experience long-term remission of clinical symptoms and inflammation, some for up to nine years. About Crohn's Disease Crohn's Disease is a chronic inflammatory disease of the gastrointestinal tract. The disease most commonly affects the lower small intestine and the large intestine. Symptoms of Crohn's Disease include abdominal pain, diarrhoea, fever and weight loss. In severe cases, the intestine can become blocked or obstructed, requiring surgery.

Young patients with Crohn's Disease may also suffer growth retardation. Patients suffering Crohn's Disease are conventionally treated with drugs aimed at reducing inflammation and other associated symptoms. The cause of Crohn's Disease is unknown, thus the standard treatments aim to treat symptoms rather than the cause of the disease. The bacterium Mycobacterium avium ss. paratuberculosis (MAP) is the lead candidate as an infectious cause of Crohn's Disease. By targeting the MAP infection, MyocondaR is designed to address a possible source of the disease, rather than attempting to merely alleviate its symptoms.

Except for historical information, this news release may contain forward-looking statements that reflect the Company's current expectation regarding future events. These forward looking statements involve risk and uncertainties, which may cause but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.

CONTACTS:

Company Media & Investor Relations

Patrick McLean - Chief Executive Officer Fay Weston - Talk Biotech

T: (02) 9266 0440 T: +61 422 206036

E: pmclean@giacondalimited.com E: fayweston@talkbiotech.com.au Fay Weston Director Talk Biotech T: 02 8812 5030 M: 0422 206036 E:fayweston@talkbiotech.com.au


'"/>




Related medicine technology :

1. FDA approves IND on Lead Product M6G
2. ChemoCentryx Presents Positive Phase 2 Clinical Data for Traficet-EN in Crohns Disease at the Digestive Disease Week 2007 Conference
3. Enzo Biochem Individualized Oral Immune Regulation Therapy May Be Effective Approach to Treating Crohns Disease
4. UCB Presents Long-Term CImzia Data in Crohns Disease
5. New Analysis of Data Shows Treatment With Abbotts Humira (Adalimumab) Significantly Reduced Disease-Related Hospitalization for Patients with Crohns Disease
6. Appendicitis: Evolving Tools to Diagnose a Classic Disease
7. Non-Invasive Diagnostic Tests for Celiac Disease
8. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Samaritans Alzheimers Drug Caprospinol Suggests Brain May be Able to Heal From Alzheimers Disease
11. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... -- The ALS Association, in partnership with ALS Finding a Cure, ... biomarker to track TDP43 aggregation. The successful team(s) with the ... investment. --> --> ... in the brain and the spinal cord. Eventually, people with ... which often leads to total paralysis and death within two ...
(Date:2/10/2016)... -- LexisNexis® Risk Solutions, a leading provider of data, ... LexisNexis Provider Performance Monitor , a clinical ... the quality and efficiency of provider networks through ... measuring provider performance through Provider Performance Monitor, payers ... improve the patient experience and reduce costs, as ...
(Date:2/10/2016)... SPRINGS, Florida , February 10, 2016 ... Pharmaceuticals, Inc. (NASDAQ: ADMS ) and Celldex Therapeutics, Inc. ... Inc. (NASDAQ: MDVN ), Adamas Pharmaceuticals, Inc. (NASDAQ: ... --> Today,s latest Orphan Drug Designations become vitally ... by the FDA to novel drugs and biologics which are ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... February 10, 2016 , ... Early this week, Team Iconic at J. Walter ... KITKAT as the first global confectionery brand sourced from 100% sustainable cocoa. , The ... of their product, through activities that focus on better farming, better lives and better ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... to expand dental health services to the developmentally disabled in the Coachella Valley. ... operations to a new facility at 71-949 Highway 111, Suite 100-B, in Rancho ...
(Date:2/10/2016)... ... February 10, 2016 , ... InDemand Interpreting , a ... partnered with Heart City Health Center to improve access to language ... City Health Center has provided the Elkhart community with access to high quality, ...
(Date:2/10/2016)... ... 10, 2016 , ... The Wickman Agency in Garland, TX ... local community. Pledging to select a new beneficiary every 60 days, the agency ... goal is to bring community awareness to important local causes by forming campaigns ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... his office is now offering a variety of comprehensive procedures for facial enhancement. ... lift, facial volume restoration, lip enhancement and nasal reshaping. , As a ...
Breaking Medicine News(10 mins):